These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 4472376)

  • 21. Tissue distribution, circulating half-life, and excretion of intravenously administered protamine sulfate.
    DeLucia A; Wakefield TW; Kadell AM; Wrobleski SK; VanDort M; Stanley JC
    ASAIO J; 1993; 39(3):M715-8. PubMed ID: 8268631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring of blood coagulation in open heart surgery. II. Use of individualized dosages of heparin and protamine controlled by activated coagulation times.
    Dercksen SJ; Linssen GH
    Acta Anaesthesiol Belg; 1980; 31(2):121-8. PubMed ID: 7468138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticoagulant monitoring and neutralization during open heart surgery--a rapid method for measuring heparin and calculating safe reduced protamine doses.
    Umlas J; Taff RH; Gauvin G; Swierk P
    Anesth Analg; 1983 Dec; 62(12):1095-9. PubMed ID: 6650893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A cytophotometric and karyometric study of the combined effect of thio-TEPA and protamine on tumor cells in tissue culture].
    Smertenko II; Brodskiĭ VIa; Braude AI
    Biull Eksp Biol Med; 1967 May; 63(5):77-80. PubMed ID: 4988364
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of acronycine on nucleic acid synthesis and population growth in mammalian tumor cell cultures.
    Gout PW; Dunn BP; Beer CT
    J Cell Physiol; 1971 Aug; 78(1):127-38. PubMed ID: 5286389
    [No Abstract]   [Full Text] [Related]  

  • 26. [Heparin monitoring during cardiopulmonary bypass in congenital heart surgery].
    Isomatsu Y; Imai Y; Seo K; Terada M; Aoki M; Shin'oka T
    Kyobu Geka; 2000 Nov; 53(12):1001-4. PubMed ID: 11079303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of regulating blood clotting with heparin and its antagonists on mast cells].
    Efimov VS; Rozkin MIa; Poberiĭ IA; Lindner DP
    Farmakol Toksikol; 1981; 44(1):80-5. PubMed ID: 7262304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of increased glomerular permeability on the localization of immune aggregates and protamine-heparin aggregates in the rat.
    Weening JJ; Grond J; Hoedemaeker PJ
    Lab Invest; 1983 Nov; 49(5):619-25. PubMed ID: 6632777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Experimental study of the heparin antagonist protamine chloride].
    Efimov VS
    Farmakol Toksikol; 1968; 31(5):601-4. PubMed ID: 5707736
    [No Abstract]   [Full Text] [Related]  

  • 31. Protamine-heparin membrane for cell microencapsulation.
    Tatarkiewicz K; Sitarek E; Fiedor P; Sabat M; Orlowski T
    Transplant Proc; 1994 Dec; 26(6):3509. PubMed ID: 7998252
    [No Abstract]   [Full Text] [Related]  

  • 32. Complexes of a modified low-molecular-weight heparin with protamine are predominantly cleared by a macrophage scavenger receptor-mediated process in rats.
    Stehle G; Wunder A; Sinn H; Schrenk HH; Friedrich EA; Dempfle CE; Maier-Borst W; Heene DL
    J Surg Res; 1995 Feb; 58(2):197-204. PubMed ID: 7861773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of postoperative heparin rebound following cardiopulmonary bypass.
    Pifarré R; Babka R; Sullivan HJ; Montoya A; Bakhos M; El-Etr A
    J Thorac Cardiovasc Surg; 1981 Mar; 81(3):378-81. PubMed ID: 7464201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protamine sulfate administration and the cardiovascular system.
    Gourin A; Streisand RL; Greineder JK; Stuckey JH
    J Thorac Cardiovasc Surg; 1971 Aug; 62(2):193-204. PubMed ID: 5560501
    [No Abstract]   [Full Text] [Related]  

  • 35. Altered localization of protamine-heparin complexes in aminonucleoside nephrosis.
    Seiler MW; Hoyer JR; Krueger TE
    Lab Invest; 1980 Jul; 43(1):9-17. PubMed ID: 6993788
    [No Abstract]   [Full Text] [Related]  

  • 36. A unified method for regional anticoagulation of blood.
    Durie MD; Hansebout RR; Peterson EW; Ringer TR
    Am J Surg; 1970 Sep; 120(3):341-5. PubMed ID: 5456917
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety issues in heparin and protamine administration for extracorporeal circulation.
    Jobes DR
    J Cardiothorac Vasc Anesth; 1998 Apr; 12(2 Suppl 1):17-20. PubMed ID: 9583571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [On the cytotoxic action of basic substances].
    Keller R
    Helv Physiol Pharmacol Acta; 1967; 25(2):CR195-8. PubMed ID: 5588165
    [No Abstract]   [Full Text] [Related]  

  • 39. Uptake of heparin by peritoneal macrophages.
    Mims CA
    Aust J Exp Biol Med Sci; 1969 Feb; 47(1):157-8. PubMed ID: 5772572
    [No Abstract]   [Full Text] [Related]  

  • 40. Pinocytosis.
    Jou TC
    Taiwan Yi Xue Hui Za Zhi; 1967 Jun; 66(6):325-32. PubMed ID: 5238908
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.